And there goes the hope that they were just more efficient in working through the available data...
The head of the regulatory agency refers to a "rolling review". Perhaps they are confident enough so far that they are willing to roll this out to the most vulnerable, if they've found that their risk of side effects (even with high error bars) is lower than their risk of getting coronavirus.
That would then buy more data which will inform continued rollout to the less at-risk population.